Subtype-specific circadian clock dysregulation modulates breast cancer biology, invasiveness, and prognosis.

Breast Cancer Circadian Data Ordering Circadian Medicine Estrogen Receptor Informatics Metastasis Prognosis Rhythm Strength

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
19 May 2023
Historique:
pubmed: 9 6 2023
medline: 9 6 2023
entrez: 9 6 2023
Statut: epublish

Résumé

Studies in shift workers and model organisms link circadian disruption to breast cancer. However, molecular rhythms in non-cancerous and cancerous human breast tissues are largely unknown. We reconstructed rhythms informatically, integrating locally collected, time-stamped biopsies with public datasets. For non-cancerous tissue, the inferred order of core-circadian genes matches established physiology. Inflammatory, epithelial-mesenchymal transition (EMT), and estrogen responsiveness pathways show circadian modulation. Among tumors, clock correlation analysis demonstrates subtype-specific changes in circadian organization. Luminal A organoids and informatic ordering of Luminal A samples exhibit continued, albeit disrupted rhythms. However, CYCLOPS magnitude, a measure of global rhythm strength, varied widely among Luminal A samples. Cycling of EMT pathway genes was markedly increased in high-magnitude Luminal A tumors. Patients with high-magnitude tumors had reduced 5-year survival. Correspondingly, 3D Luminal A cultures show reduced invasion following molecular clock disruption. This study links subtype-specific circadian disruption in breast cancer to EMT, metastatic potential, and prognosis.

Identifiants

pubmed: 37293090
doi: 10.1101/2023.05.17.540386
pmc: PMC10245642
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG068577
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227485
Pays : United States

Déclaration de conflit d'intérêts

Declaration of interests J.B.H. is on the scientific advisory board for Synchronicity Pharma. The remaining authors declare no competing interests.

Auteurs

Jan A Hammarlund (JA)

School of Biomedical Engineering, Science and Health Systems. Drexel University, Philadelphia, PA, USA.

Shi-Yang Li (SY)

Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Gang Wu (G)

Divisions of Human Genetics and Immunobiology, Center for Circadian Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Jia-Wen Lian (JW)

School of Biomedical Engineering, Science and Health Systems. Drexel University, Philadelphia, PA, USA.

Sacha J Howell (SJ)

Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Rob Clarke (R)

Breast Biology Group, Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Antony Adamson (A)

School of Biomedical Engineering, Science and Health Systems. Drexel University, Philadelphia, PA, USA.

Cátia F Gonçalves (CF)

School of Biomedical Engineering, Science and Health Systems. Drexel University, Philadelphia, PA, USA.

John B Hogenesch (JB)

Divisions of Human Genetics and Immunobiology, Center for Circadian Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Qing-Jun Meng (QJ)

Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

Ron C Anafi (RC)

Department of Medicine, Chronobiology and Sleep Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.

Classifications MeSH